KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBT Margin (2016 - 2025)

Alnylam Pharmaceuticals' EBT Margin history spans 16 years, with the latest figure at 7.86% for Q4 2025.

  • For Q4 2025, EBT Margin rose 4056.0% year-over-year to 7.86%; the TTM value through Dec 2025 reached 10.45%, up 2723.0%, while the annual FY2025 figure was 8.7%, 2549.0% up from the prior year.
  • EBT Margin reached 7.86% in Q4 2025 per ALNY's latest filing, down from 22.46% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 22.46% in Q3 2025 to a low of 153.59% in Q3 2022.
  • Average EBT Margin over 5 years is 52.96%, with a median of 43.34% recorded in 2023.
  • Peak YoY movement for EBT Margin: plummeted -4474bps in 2022, then skyrocketed 17367bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 100.68% in 2021, then surged by 39bps to 61.79% in 2022, then skyrocketed by 49bps to 31.31% in 2023, then dropped by -4bps to 32.7% in 2024, then surged by 124bps to 7.86% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBT Margin are 7.86% (Q4 2025), 22.46% (Q3 2025), and 4.57% (Q2 2025).